Drugs

, Volume 65, Issue 12, pp 1697–1713 | Cite as

Rifaximin

A Review of its Use in the Management of Traveller’s Diarrhoea
Adis Drug Evaluation

Summary

Abstract

Oral rifaximin, a semisynthetic rifamycin derivative, is an effective and well tolerated antibacterial for the management of adults with non-invasive traveller’s diarrhoea. Rifaximin was significantly more effective than placebo and no less effective than ciprofloxacin in reducing the duration of diarrhoea after treatment initiation for illness contracted during travel to diverse geographic locations. While rifaximin is effective in patients with Escherichia coli-predominant traveller’s diarrhoea, it appears ineffective in patients infected with inflammatory or invasive enteropathogens. Rifaximin has a broad spectrum of antibacterial activity in vitro and undergoes negligible systemic absorption (<0.4%). In contrast to systemically absorbed antibacterials, such as the fluoroquinolones and macrolides, the acquisition of resistance to rifaximin would have limited consequences for global public health, as rifaximin has no role in the management of systemic infections. Rifaximin shows promise as chemoprophylaxis against traveller’s diarrhoea and is a valuable new option for the management of traveller’s diarrhoea caused by non-invasive bacterial strains.

Pharmacological Properties and Antibacterial Activity

Rifaximin inhibits bacterial RNA synthesis by its action on the β-subunit of the DNA-dependent RNA polymerase. It is active against the bacterial enteropathogens from diverse global locations that commonly cause traveller’s diarrhoea including enterotoxigenic E. coli (ETEC), enteroaggregative E. coli(EAEC), Salmonella spp. and Shigella spp. Minimum inhibitory concentrations required to inhibit the growth of 90% of isolates (MIC90S) against these enteropathogens ranged from 4 to 64 mg/L in isolates from stool samples for patients with traveller’s diarrhoea.

Rifaximin does not appear to select for resistance among Gram-negative and -positive intestinal flora, although a small study reported the development of resistance to rifaximin (in vitro concentration threshold of 100 ji.g/mL) by aerobic and anaerobic bacteria, including E. coli, in the gastrointestinal tract; however, resistant strains were undetectable 12 weeks post-treatment (>75% of these strains were undetectable within 1–2 weeks).

Rifaximin undergoes negligible systemic absorption and does not appear to accumulate following repeated administration. Maximum plasma concentrations (Cmax) of rifaximin after administration of a single oral dose of rifaximin 400mg to healthy male volunteers were 3.80 ng/mL under fasting conditions and 9.63 ng/mL after a high fat meal. Mean Cmax values in volunteers treated with rifaximin 200mg three times daily for 3 days upon development of diarrhoea or dysentery after challenge with Shigella flexneri were 1.63 ng/mL on day 1 and 1.23 ng/mL on day 3. Rifaximin treatment was not effective in these volunteers; however, prophylactic rifaximin 200mg three times daily for 3 days was effective in preventing shigellosis in volunteers challenged with S. flexneri.

Rifaximin is excreted mainly in the faeces mostly as the unchanged drug. Faecal concentrations of rifaximin reached ≈8000 μg/g after oral administration of 400mg twice daily for 3 days, exceeding the MIC90 values of ETEC and EAEC by ≈250-fold. Because of this minimal systemic absorption, in vitro susceptibility data may not reliably predict antibacterial activity in the gastrointestinal tract.

Therapeutic Efficacy

Randomised, double-blind comparative trials have shown that oral rifaximin is significantly more effective than placebo, and no less effective than ciprofloxacin in shortening the duration of diarrhoea after initiation of treatment in non-indigenous travellers with traveller’s diarrhoea. In these trials, enteropathogen detection rates were generally low in pretreatment stool samples, with ETEC the most common pathogen identified in samples in which enteropathogens were detected.

The median time from the initiation of treatment to the passage of the last unformed stool (TLUS; primary endpoint) was significantly shorter (32.5 and 32.9 hours) in recipients of rifaximin 200 or 400mg three times daily for 3 days who contracted traveller’s diarrhoea during travel to Guatemala, Mexico or Kenya than in placebo recipients (60.0 hours). In adults with traveller’s diarrhoea contracted during travel to India, Mexico, Guatemala and Peru, median TLUS was 32.0 hours in recipients of rifaximin 200mg three times daily versus 65.5 hours in placebo recipients and 28.8 hours in recipients of ciprofloxacin 500mg twice daily.

Median TLUS was similar in patients with traveller’s diarrhoea contracted during travel to Mexico or Jamaica who received twice-daily rifaximin 400mg or ciprofloxacin 500mg (25.7 vs 25.0 hours).

Rifaximin appears ineffective in patients with fever and bloody stools and in patients with inflammatory or invasive pathogens in pretreatment stool samples (including patients infected with Campylobacter jejuni).

Prophylactic administration of rifaximin 200mg once, twice or three times daily for 2 weeks resulted in a significantly lower incidence of traveller’s diarrhoea (12%, 19% and 13%, respectively) than administration of placebo (54%) in travellers to Mexico. Again, ETEC was the most common enteropathogen identified in stool samples.

Tolerability

Oral rifaximin is well tolerated in adults with traveller’s diarrhoea, with the incidence and type of adverse events similar to that with placebo in clinical trials. Serious adverse event and treatment discontinuation rates were low: one rifaximin recipient experienced a serious adverse event (dysentery) that was considered unrelated to treatment and three rifaximin recipients discontinued treatment because of adverse events (possibly or probably treatment-related in one recipient).

Across the two largest trials, adverse events were commonly gastrointestinal, generally of mild or moderate intensity and occurred with an overall incidence of 44%, 24% and 54% in recipients of rifaximin 600 mg/day, ciprofloxacin 1000 mg/day or placebo. The rate of adverse events may be reflective of the severity of the underlying traveller’s diarrhoea: in participants of the largest trial, numerically more rifaximin and placebo recipients than ciprofloxacin recipients had faecal leukocyte-positive illness, and inflammatory or invasive pathogens or blood in baseline stool samples. In recipients of rifaximin 800 mg/day or ciprofloxacin 1000 mg/day enrolled in the other phase III trial, adverse events were mild and nonspecific, occurring in 33% and 36% of patients.

Across phase II and phase III trials, no clinically important changes in white blood cells, haemoglobin, platelets or liver enzyme levels were reported following rifaximin treatment.

Keywords

Placebo Recipient Stool Sample Rifaximin Shigellosis Unformed Stool 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Ericsson CD. Travellers’ diarrhoea. Int J Antimicrob Agents 2003 Feb; 21(2): 116–24PubMedCrossRefGoogle Scholar
  2. 2.
    Castelli F, Pezzoli C, Tomasoni L. Epidemiology of travelers’ diarrhea. J Travel Med 2001 Dec; 8 Suppl. 2: S26–30PubMedCrossRefGoogle Scholar
  3. 3.
    Okhuysen P, Jiang ZD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99: 1774–8PubMedCrossRefGoogle Scholar
  4. 4.
    Casburn-Jones AC, Farthing MJG. Traveler’s diarrhea. Gastroenterol Hepatol 2004; 19(6): 610–8CrossRefGoogle Scholar
  5. 5.
    de Bruyn G. Diarrhoea. Clin Evid 2000; 3: 320–6Google Scholar
  6. 6.
    Vila J, Levy SB. Antimicrobial resistance. In: Ericsson CD, DuPont HL, Steffen RS, editors. Travelers’ diarrhea. Hamilton (ONT): BC Decker Inc., 2003: 58–75Google Scholar
  7. 7.
    Huang DB, DuPont HL. Rifaximin-a novel antimicrobial for enteric infections. J Infect 2005; 50: 97–106PubMedCrossRefGoogle Scholar
  8. 8.
    DuPont HL. Treatment of travelers’ diarrhea. J Travel Med 2001 Dec; 8 Suppl. 2: S31–3PubMedCrossRefGoogle Scholar
  9. 9.
    Steffen R. Rifaximin: a nonabsorbed antimicrobial as a new tool for treatment of travelers’ diarrhea. J Travel Med 2001 Dec; 8 Suppl. 2: S34–9PubMedCrossRefGoogle Scholar
  10. 10.
    Salix Pharmaceuticals Inc. XIFAXIN prescribing information, 2004 Jun [online]. Available from URL: http://www.salix.com [Accessed 2005 Feb 23]Google Scholar
  11. 11.
    Normix: summary of product characteristics. Italy: Alfa Wassermann S.p.A., 2005 Jun 1Google Scholar
  12. 12.
    Rifacol: summary of product characteristics. Greece: Alfa Wassermann S.p.A., 2001Google Scholar
  13. 13.
    Normix: summary of product characteristics. Czech Republic: Alfa Wassermann S.p.A., 2001Google Scholar
  14. 14.
    Flonorm: summary of product characteristics. Mexico: Alfa Wassermann S.p.A., 2003Google Scholar
  15. 15.
    Normix: product information leaflet. Lebanon: Alfa Wassermann S.p.A., 2002 Dec 18Google Scholar
  16. 16.
    Lormyx: product information leaflet. China: Alfa Wassermann S.p.A., 2004Google Scholar
  17. 17.
    Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995 Mar; 49: 467–84PubMedCrossRefGoogle Scholar
  18. 18.
    Jiang ZD, DuPont HL. Rifaximin: in vitro and in vivo antibacterial activity: a review. Chemotherapy 2005; 51 Suppl. 1: 67–72CrossRefGoogle Scholar
  19. 19.
    Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; fifteenth informational supplement. Wayne (PA): Clinical and Laboratory Standards Institute, 2005 Jan. Report no. M100-S15 (M7)Google Scholar
  20. 20.
    Gomi H, Jiang ZD, Adachi JA, et al. In vitro antimicrobial susceptibility testing of bacterial enteropathogens causing traveler’s diarrhea in four geographic regions. Antimicrob Agents Chemother 2001 Jan; 45(1): 212–6PubMedCrossRefGoogle Scholar
  21. 21.
    Sierra JM, Ruiz J, Navia MM, et al. In vitro activity of rifaximin against enteropathogens producing traveler’s diarrhea. Antimicrob Agents Chemother 2001 Feb; 45(2): 643–4PubMedCrossRefGoogle Scholar
  22. 22.
    DuPont HL, Jiang ZD, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001 Dec 1; 33: 1807–15PubMedCrossRefGoogle Scholar
  23. 23.
    Steffen R, Sack DA, Riopel L, et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am J Gastroenterol 2003 May; 98: 1073–8PubMedCrossRefGoogle Scholar
  24. 24.
    DuPont HL, Jiang ZD. Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci. Clin Microbiol Infect 2004 Nov; 10(11): 1009–11PubMedCrossRefGoogle Scholar
  25. 25.
    De Leo C, Eftimiadi C, Schito GC. Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin. Drugs Exp Clin Res 1986; 12(12): 979–81PubMedGoogle Scholar
  26. 26.
    Soro O, Pesce A, Raggi M, et al. Selection of rifampicin-resistant Mycobacterium tuberculosis does not occur in the presence of low concentrations of rifaximin. Clin Microbiol Infect 1997; 3: 147–51PubMedCrossRefGoogle Scholar
  27. 27.
    Taylor D, McKenzie R, Durbin A, et al. Double-blind, placebo-controlled trial to evaluate the use of rifaximin (200 mg TID) to prevent diarrhea in subjects challenged with Shigella flexneri 2a [abstract 2079 plus poster]. 53rd Meeting of the American Society of Tropical Medicine and Hygiene; 2004 Nov 7–11; Miami (FL)Google Scholar
  28. 28.
    Trapnell CB, Taylor DN, Montgomery C, et al. Systemic pharmacokinetics of rifaximin in subjects with shigellosis. Clin Pharmacol Ther 2005 Feb; 77(2): 60CrossRefGoogle Scholar
  29. 29.
    FDA. Medical review: application number 21-361. Clinical study RFID3001 [online]. Available from URL: http:// www.fda.gov/cder/ [Accessed 2005 Apr 26]Google Scholar
  30. 30.
    Descombe JJ, Dubourg D, Picard M, et al. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int J Clin Pharmacol Res 1994; 14(2): 51–6PubMedGoogle Scholar
  31. 31.
    Rizzello F, Gionchetti P, Venturi A, et al. Rifaximin systemic absorption in patients with ulcerative colitis. Eur J Clin Pharmacol 1998 Mar; 54: 91–3PubMedCrossRefGoogle Scholar
  32. 32.
    Jiang ZD, Ke S, Palazzini E, et al. In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000 Aug; 44: 2205–6PubMedCrossRefGoogle Scholar
  33. 33.
    DuPont HL, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion 1998; 59(6): 708–14PubMedCrossRefGoogle Scholar
  34. 34.
    DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers’ diarrhea. Ann Intern Med 2005 May 17; 142(10): 805–12PubMedGoogle Scholar
  35. 35.
    Com-Nougue C, Rodary C, Patte C. How to establish equivalence when data are censored: a randomized trial of treatments for B non-Hodgkin lymphoma. Stat Med 1993; 12: 1353–64PubMedCrossRefGoogle Scholar
  36. 36.
    Infante RM, Ericsson CD, Jiang ZD, et al. Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy. Clin Gastroenterol Hepatol 2004 Feb; 2(2): 135–8PubMedCrossRefGoogle Scholar
  37. 37.
    Vial P, Mathewson J, DuPont H, et al. Comparison of two assay methods for patterns of adherence to HEp-2 cells of Escherichia coli for patients with diarrhoea. J Clin Microbiol 1990; 28: 882–5PubMedGoogle Scholar
  38. 38.
    World Health Organization. WHO model prescribing information-drugs used in bacterial infections [online]. Available from URL: http//:www.who.int/medicines/library/bacterial_model_pres/bacterial_content.shtml [Accessed 2005 Feb 24]Google Scholar
  39. 39.
    Butterton JR, Calderwood SB. Acute infectious diarrheal diseases and bacterial food poisoning. In: Braunwald E, Fauci A, Hauser S, et al, editors. Harrison’s principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001: 834–9Google Scholar
  40. 40.
    Steffen R, Castelli F, Nothdurft H. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers’ diarrhea. J Travel Med 2005; 12(2): 102–7PubMedCrossRefGoogle Scholar
  41. 41.
    Boedeker E. Vaccines for enterotoxigenic Escherichia coli: current status. Curr Opin Gastroenterol 2005; 21: 15–9PubMedGoogle Scholar
  42. 42.
    Gorbach SL. How to hit the runs for fifty million travelers at risk. Ann Intern Med 2005 May 17; 142(10): 861–2PubMedGoogle Scholar
  43. 43.
    DuPont HL. Travelers’ diarrhea: antimicrobial therapy and chemoprevention. Nat Clin Prac Gastroenterol Hepatol 2005 Apr; 2(4): 191–8CrossRefGoogle Scholar
  44. 44.
    Caeiro JP, DuPont HL. Management of travellers’ diarrhoea. Drugs 1998; 56(1): 73–81PubMedCrossRefGoogle Scholar
  45. 45.
    Scarpignato C, Rampai P. Prevention and treatment of traveler’s diarrhea: a clinical pharmacological approach. Chemotherapy 1995; 41 Suppl. 1: 48–81CrossRefGoogle Scholar
  46. 46.
    Bouckenooghe A, Kass B. General principles in self-treating travelers’ diarrhea abroad. In: Ericsson CD, DuPont HL, Steffen RS, editors. Traveler’s diarrhea. Hamilton (ONT): BC Decker Inc., 2003: 200–16Google Scholar
  47. 47.
    DuPont HL, Mattila L. Antimicrobial treatment: an algorithmic approach. In: Ericsson CD, DuPont HL, Steffen RS, editors. Travelers’ diarrhea. Hamilton (ONT): BC Decker Inc, 2003: 227–37Google Scholar
  48. 48.
    Gascon J, Corachan M. Aetiology, epidemiology, and management of traveller’s diarrhoea. Rev Med Microbiol 2003; 14(3): 73–8CrossRefGoogle Scholar
  49. 49.
    Adachi JA, Ericsson CD, Jiang Z-D, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travelers with acute diarrhea acquired in Mexico. Clin Infect Dis 2003; 37: 1165–71PubMedCrossRefGoogle Scholar
  50. 50.
    Isenbarger D, Hoge C, Srijan A, et al. Comparative antibiotic resistance of diarrheal pathogens from Vietnam and Thailand, 1996–1999. Emerg Infect Dis 2002 Feb; 8(2): 175–80PubMedCrossRefGoogle Scholar
  51. 51.
    Hoge C, Gambel J, Srijan A, et al. Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26: 341–5PubMedCrossRefGoogle Scholar
  52. 52.
    DuPont H. Are quinolones (Q) the current empiric treatment of choice for travelers’ diarrhea? [abstract no. SY07.01]. 8th Conference of the International Society of Travel Medicine; 2003 May 7–11; New YorkGoogle Scholar
  53. 53.
    Ericsson CD, DuPont HL. Rifaximin in the treatment of infectious diarrhea. Chemotherapy 2005; 51 Suppl. 1: 73–80CrossRefGoogle Scholar
  54. 54.
    Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51 Suppl. 1: 36–66CrossRefGoogle Scholar
  55. 55.
    Ericsson CD. Rifaximin: a new approach to the treatment of travelers’ diarrhea. Conclusion. J Travel Med 2001 Dec; 8 Suppl. 2: S40CrossRefGoogle Scholar
  56. 56.
    Ericsson CD, DuPont HL, Mathewson JJ, et al. Test-of-cure stool cultures for traveler’s diarrhea. J Clin Microbiol 1988; 26(5): 1047–9PubMedGoogle Scholar
  57. 57.
    Huang DB, Okhuysen PC, Jiang ZD, et al. Enteroaggregative Escherichia coli: an emerging enteric pathogen. Am J Gastroenterol 2004 Feb; 99(2): 383–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, AucklandNew Zealand

Personalised recommendations